CAM
VRTX icon

Cormorant Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cormorant Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-85,000
Closed -$15.6M – 77
2019
Q2 		$15.6M Buy
+85,000
New +$14.9M 0.9% 35

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cormorant Asset Management's VRTX Position: Q3 2019 in Review

Cormorant Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 85,000 shares — an estimated $15.6M sold.

Cormorant Asset Management first reported a position in VRTX in Q2 2019 and held it in 1 quarter. The position peaked at $15.6M in Q2 2019. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Cormorant Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Cormorant Asset Management sold 85,000 Vertex Pharmaceuticals shares in Q3 2019, an estimated $15.6M.
  • Cormorant Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Cormorant Asset Management's Vertex Pharmaceuticals position peaked at $15.6M in Q2 2019.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.